New treatment for a specific type of sarcoma using a small molecule inhibitor
Development of a novel small molecule MDM2 inhibitor for innovative sarcoma treatment
['FUNDING_SBIR_2'] · LAMASSU BIO INC · NIH-10900571
This study is testing a new drug called SA53 to see if it can help people with soft tissue sarcoma, especially those who haven't had success with other treatments, by finding the right dose and understanding how it works in the body.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | LAMASSU BIO INC (nih funded) |
| Locations | 1 site (DURHAM, UNITED STATES) |
| Trial ID | NIH-10900571 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a new drug, SA53, that targets p53 wild type sarcomas, a type of cancer. The team has conducted extensive testing to ensure the drug is safe and effective, and they plan to conduct a clinical trial to determine the best dose for patients. The trial will also assess how the drug works in the body and its potential to help patients with soft tissue sarcoma. If successful, this innovative treatment could provide a new option for patients who have not responded to other therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with p53 wild type soft tissue sarcomas who have not responded to standard treatments.
Not a fit: Patients with sarcomas that do not have the p53 wild type mutation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could offer a novel and effective treatment option for patients with p53 wild type soft tissue sarcomas.
How similar studies have performed: Other research has shown promise with similar approaches targeting p53 pathways, indicating potential for success in this novel treatment.
Where this research is happening
DURHAM, UNITED STATES
- LAMASSU BIO INC — DURHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HANNA, GABI — LAMASSU BIO INC
- Study coordinator: HANNA, GABI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Treatment, Cancers